The results of a multicentre, randomised, double-blind, placebo controlled, crossover trial of lamotrigine as add-on therapy in patients with partial seizures poorly controlled by established antiepileptic drugs (AEDs) are presented. The study consisted of two 12 week treatment periods each followed by a four week washout period. During the lamotrigine treatment phase, patients received 150 mg or 300 mg daily dose depending on their concomitant AEDs to achieve concentrations in the range 1-3 mg/L. Forty one patients were entered at four centres and all patients entered completed the study. There was a highly significant (p < 0.001) decrease in total seizure counts on lamotrigine compared with placebo. Overall, 22% of patients experienced at least a 50% reduction in the total numbers of all seizure types on lamotrigine, compared with none on placebo. When the total numbers of partial seizures (simple and complex partial) were analysed there was also a significant (p < 0.05) reduction in seizure counts on lamotrigine compared with placebo. When total numbers of secondarily generalised seizures were compared the trend for a reduction in this seizure type did not achieve significance (0.05 < p < 0.1). Concomitant AED plasma concentrations were virtually unchanged. It is concluded that lamotrigine is an effective AED in the treatment of therapy-resistant partial seizures. (7 Neurol Neurosurg Psychiatry 1993;56:448-453) Lamotrigine (3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine) is a novel antiepileptic drug (AED) chemically unrelated to the major drugs in current use. In vitro studies have suggested that lamotrigine acts at volt- The study was a multicentre, randomised, double-blind, placebo controlled, crossover trial of lamotrigine in outpatients with refractory partial seizures, as defined by the international classification.8 One of the previous crossover studies which had included 18 patients in the analysis had failed to achieve statistical significance5 and therefore it was decided that 40-50 patients should be entered into this trial to ensure the study has sufficient power to detect a drug effect. Lamotrigine or placebo was added to an existing regime of up to two established AEDs. The trial consisted of five phases ( fig 1). Patients were considered for inclusion into the trial during an initial three month baseline period. Each treatment period of 12 weeks was followed by a four week taper/washout period. Medication was tapered over the first week of the washout period and then patients were given placebo.

Three patients who developed clinical evidence of non-convulsive status epilepticus while on high doses of the investigational antiepileptic drug, tiagabine are reported. This apparently paradoxical phenomenon developed when the tiagabine dose was increased to 48 mg/day in one patient, and to 60 mg/day in two other patients, in combination with other antiepileptic drugs. Seizure control improved following reduction in tiagabine dose in one patient and discontinuation of tiagabine in the two others. The observation raises the possibility of a clinically relevant paradoxical epileptogenic effect of GABA-ergic drugs such as tiagabine.

Urinary excretion of 6-sulfatoxymelatonin (aMT.6S), the hepatic metabolite of melatonin, was measured for three consecutive 8-h intervals, beginning at 0600 h, in 30 patients with untreated active epilepsy and in 19 healthy subjects. Excretion of aMT.6S in a 24-h period in patients with active epilepsy was 77.3 +/- 55 nmol (median 68.0, range 8.7-280 nmol), significantly higher (p < 0.05) than that of healthy subjects (49.1 +/- 14 nmol, median 49.0, range 19.7-68.0 nmol). Sequential 8-h urinary aMT.6S excretion rates in patients with active epilepsy were 2.45 +/- 2.8 nmol/h (0600-1400 h), 0.83 +/- 0.5 nmol (1400-2200 h) and 6.38 +/- 5.0 nmol/h (2200-0600 h) as compared with 1.43 +/- 0.8, 1.10 +/- 0.8 and 3.81 +/- 1.3 nmol/h, respectively, in healthy subjects. Analysis of variance (ANOVA) indicated that the difference in total output resulted from greater nocturnal excretion (F = 5.58, p = 0.018). Melatonin production in untreated patients with active epilepsy is increased and has a circadian pattern with a phase difference as compared with that of normal subjects.